To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

657 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-15

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the safety and efficacy of Perrigo's product to an FDA approved product, and to Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

NCT06283979

Pressure Ulcer, Stage IV Osteomyelitis

RECRUITING PHASE2

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

NCT06618612

Diabetic Foot Ulcer

RECRUITING NA

A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis

NCT05539963

Diabetic Foot Osteomyelitis

ACTIVE_NOT_RECRUITING PHASE2

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

NCT01594762

Diabetic Foot Infection

COMPLETED PHASE3

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

NCT02427802

Foot Ulcer, Diabetic Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Secondarily Infected Traumatic Skin Lesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perrigo active

Group Type EXPERIMENTAL

Mupirocin Calcium

Intervention Type DRUG

mupirocin cream

Reference Active

Group Type ACTIVE_COMPARATOR

Mupirocin Calcium

Intervention Type DRUG

Reference mupirocin cream

Vehicle control

Group Type PLACEBO_COMPARATOR

Vehicle

Intervention Type DRUG

vehicle control cream

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mupirocin Calcium

mupirocin cream

Intervention Type DRUG

Mupirocin Calcium

Reference mupirocin cream

Intervention Type DRUG

Vehicle

vehicle control cream

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or non-pregnant females aged 18 months or older.
2. Must have a secondarily infected traumatic skin lesion such as a laceration, sutured wound, or abrasion.
3. Must have a positive baseline culture for S. aureus and/or S. pyogenes from a sample taken from the secondarily infected traumatic skin lesion.
4. Must have a positive Gram stain or Wright stain for confirmation of white blood cells in the pus/exudate from the secondarily infected traumatic skin lesion.
5. Must have a Skin Infection Rating Scale (SIRS) total score for the secondarily infected traumatic skin lesion of at least 8 at baseline.
6. Must be willing and able to understand and comply with the requirements of the study, apply the medication as instructed, and be able to complete the study.
7. Must be in general good health and free from any clinically significant disease, other than secondarily infected traumatic skin lesion(s), that might interfere with the study evaluations.

Exclusion Criteria

1. Subjects who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation.
2. Presence of any dermatological disorder that may interfere with evaluation of the subject's secondarily infected traumatic skin lesion(s).
3. Presence of bacterial skin infection that, because of depth or severity, could not be appropriately treated with a topical antibiotic.
4. Presence of secondarily infected bite or puncture wound.
5. Presence of systemic signs or symptoms of infection (fever defined as an oral temperature greater than 101°F or 38.3°C).
6. Requirement for surgical intervention for treatment of the infection prior to study entry.
7. Presence of cutaneous herpes simplex infections.
8. Use of any topical corticosteroid, topical antibiotic, or topical antifungal, on the secondarily infected target lesion, within 48 hours prior to Visit 1/Day 1.
9. Use of systemic antibiotics or systemic corticosteroids within 7 days of Visit 1/Day 1.
10. Primary or secondary immunodeficiency.
11. Diagnosed Diabetes Mellitus (controlled or uncontrolled).
12. Any uncontrolled, chronic or serious disease or medical condition that would prevent participation in a clinical trial, or, in judgment of the investigator, would put the subject at undue risk or might confound the study assessments.
13. History of hypersensitivity or allergy to mupirocin and/or any ingredient in the study medication.
14. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
15. Subjects who, in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.

Minimum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No